Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Phico Therapeutics Awarded $18.2 million USD CARB-X Funding

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Phico Therapeutics Ltd, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to $18.2 million USD (circa. £13.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

Phico Therapeutics notes the funding will support the progression of Phico’s lead product SASPject™ PT3.9 through clinical trials with $5.3 million USD (circa. £3.8 million GBP) available immediately and a further $12.9 million (circa. £9.4 million GBP) contingent on reaching specific project milestones.

SASPject PT3.9 has been developed for the intravenous treatment of hospital infections due to the bacterium, Pseudomonas aeruginosa using Phico’s SASPject platform. The platform utilises unique antibacterial small acid-soluble spore proteins (SASP) which target selected bacterial species to inactivate bacterial DNA, stopping them from metabolizing or reproducing. The Phase I clinical trials will be first-in-man, intravenous studies and will focus on establishing the safety and kinetics of PT3.9 in healthy volunteers and, potentially, patients with ventilated hospital-acquired pneumonia and ventilator associated pneumonia.

  1. aeruginosa is a leading cause of pneumonia in hospital patients, especially those on a ventilator. The increasing incidence of strains showing multi-drug antibiotic resistance has resulted in the U.S. Centers for Disease Control and Prevention classifying P. aeruginosaas a serious threat to human health. With antimicrobial resistance also listed as a Top 3 Global Health Threat by the World Health Organisation, the SASPject platform could provide a new range of innovative antibiotic treatments to help overcome this challenge.

Dr. Heather Fairhead, Phico Founder, and CEO said: “To receive funding from CARB-X is important validation for our SASPject technology platform and its potential in fighting bacterial resistance. It has been awarded at the end of a thorough due diligence process which reinforces the credibility of the company and our team – I am delighted to now look forward to progressing our lead product to clinical trials and developing a product pipeline that will advance the science of antibacterial therapy and in time, save millions of lives round the world.”

“Phico Therapeutics innovative approach delivers the antibiotic effect of SASPs by using engineered bacteriophages to precisely target P. aeruginosa infections in the lungs,” said Erin Duffy, R&D Chief of CARB-X. “This approach has the potential to target bacteria without damaging other cells, and without contributing to the rise of resistance. If successful, this new intravenous drug could transform the way patients with ventilator-associated pneumonia are treated in hospitals, and save lives.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine